A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, sequential dose exploration study of single agent EEDVSMit
administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance
dosing, in children with recurrent/refractory solid or CNS tumours.